Xbiome Employee Directory
Biotechnology ResearchMassachusetts, United States51-200 Employees
Xbiome is a biotechnology research company focused on gut microbiome–targeted therapeutics, applying artificial intelligence to accelerate drug development. Based in Cambridge, Massachusetts, the company aims to advance medical treatments and precise, personalized management of gut health. It combines microbial technologies, AI, and bioinformatics to support a platform for microbiome drug development within the biotech sector. The company collaborates with external partners to bring microbiome therapies to broader markets, including Greater China, where it has licensing and development arrangements for Aurealis Therapeutic’s AUP-16 four-in-one therapy. In 2022, Xbiome acquired the clinical-stage M201 program from Assembly Biosciences, expanding its clinical portfolio.